Modulatory effects of meloxicam on cardiotoxicity and antitumor activity of doxorubicin in mice
This study was undertaken to assess the possible modulatory effects and mechanisms of meloxicam, a cyclooxygenase-2 inhibitor, on the antitumor activity and cardiotoxicity of doxorubicin in a mice model of mammary carcinoma.
Solid tumor mass was developed in female albino mice using Ehrlich carcinoma cells. Forty mice-bearing tumor were divided randomly into four groups for treatment: with saline, meloxicam 10 mg/kg, doxorubicin 5 mg/kg and meloxicam 1 h ahead of doxorubicin, twice weekly for 2 weeks. Tumor volume was followed up and cardiac protective utility was estimated via measuring heart and serum parameters.
Meloxicam expressed a non-significant increase in doxorubicin antitumor activity. Conversely, meloxicam significantly (p < 0.01) mitigated doxorubicin-induced elevation of serum cardiac enzymes [creatine kinase, lactate dehydrogenase and troponin-I]; cardiac lipid peroxidations marker; cardiac active caspase-3 content; and cardiac prostaglandin E2 content. Meloxicam significantly abrogated doxorubicin-induced disturbance in heart histology and relative heart weight to body weight. Meloxicam normalized doxorubicin-induced suppression in heart antioxidant enzymes activities and gene expressions [superoxide dismutase, glutathione peroxidase (GSH-Px) and catalase], and heart GSH content. In addition, meloxicam ameliorated doxorubicin-induced disturbance in phase II metabolizing enzyme, cardiac quinone reductase (QR), at activity level and mRNA expression.
Meloxicam protects heart against doxorubicin toxicity without affecting its antitumor activity against solid mammary cancer model in mice. This protective effect is attributed to antioxidant effect, antiradical effect, antiinflammatory action, antiapoptotic effect and induction of QR enzyme.
KeywordsDoxorubicin Oxidative stress Quinone reductase Cyclooxygenase-2 inhibitors Meloxicam
We are deeply thankful to the animal house technician Mr. Islam Farouk, Pharm. B.Sc., department of Pharmacology, Faculty of Pharmacy, King Abdel-Aziz University, Jeddah, K.S.A., for his kind accommodation of laboratory animals and support during animal experiment. Also we are indebted to Dr. Fares El-Tom, a lecture of histology at Taibah University, K.S.A., for his invaluable contribution in histological examination of cardiac tissue. The authors disclosed receipt the full financial support and funding from the Deanship of Scientific Research; Taibah University—Almadinah Almunawarah; Saudi Arabia (Grant Number 1091–1433) for this study.
Conflict of interest
All authors have nothing to declare.
- 2.Kufe DW, Holland JF, Frei E (2003) American cancer society: cancer medicine 6. BC Decker, HamiltonGoogle Scholar
- 8.Badary OA, Awad AS, Abdel-Maksoud S, Hamada FM (200) Cardiac DT-diaphorase contributes to the detoxification system against doxorubicin-induced positive inotropic effects in guinea-pig isolated atria. Clin Exp Pharmacol Physiol 31(12):856–861Google Scholar
- 23.Osman A, Sayed-Ahmed M, Khayyal M, El Merzebani M (1993) Hyperthermic potentiation of cisplatin on solid Ehrlich carcinoma. Tumouri 79:268–272Google Scholar
- 26.Bancroft J, Stevens A (1996) Enzyme histochemistry: theory and practice of histological techniques. Churchill Livingstone, New YorkGoogle Scholar
- 35.Al-Shabanah OA, Osman AM, Al-Harbi MM, Al-Gharably NM, Al-bekairi AM, El-Merzabani MM (1996) Effect of hyperthermia on the action of methotrexate against the growth of Ehrlich ascites carcinoma cells. Med Sci Res 24:275–277Google Scholar
- 43.Powis G, Gasdaska PY, Gallegos A, Sherrill K, Goodman D (1995) Overexpression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs. Anticancer Res 15:1141–1145PubMedGoogle Scholar